Cassava Sciences (NASDAQ:SAVA) focuses primarily on the discovery and development of drugs for neurodegenerative diseases, including Alzheimer's disease. The company's innovative approach includes simufilam, its lead drug candidate designed to treat Alzheimer's by restoring the normal shape and function of a key brain protein. Additionally, Cassava is working on an early detection blood test for Alzheimer's, aiming to identify the disease in its nascent stages. With a commitment to advancing Alzheimer's research and providing new hope for patients and families affected by this condition, Cassava Sciences is dedicated to improving outcomes in the field of neurology.